Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Just days after announcing sweeping job cuts at NHS England, UK Prime Minister Keir Starmer has said that the government ...

President Donald Trump has withdrawn his nomination of Dave Weldon to lead the CDC, just hours before he was due to appear in ...

Gedeon Richter's drug is the only licensed GnRH antagonist option and, unlike GnRH agonists like Takeda's Prostap ...

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...

They are following in the footsteps of NHS chief executive Amanda Pritchard and medical director Sir Stephen Powis, who have ...

Philadelphia-based Endo sold its international pharma unit to Knight Therapeutics this week for up to $99 million, while Ireland-headquartered Mallinckrodt sold Therakos, a specialist in ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...